Study Phase 4

Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

  • PDF icon for CSR Summary CSR Summary Not Available
  • Globe symbol for NCT Number NCT03267576
  • Notebook for Primary Citation Primary Citation Not Available
  • Spreadsheet for Data Specification Data Specification Not Yet Available

Trial Information

Generic NameCanagliflozinProduct NameINVOKANA®Therapeutic AreaCardiovascular and Metabolic DiseasesEnrollment64% Female44.4%% White0.0%
Product ClassSodium-Glucose Co-Transporter 2 (SGLT2) InhibitorSponsor Protocol Number28431754DIA4026Data PartnerJohnson & JohnsonCondition StudiedDiabetes MellitusMean/Median Age (Years)45.3

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.